UK researchers evaluated 632 type 2 diabetes patients with insufficient glycemic control and found that those who received oral semaglutide had significant reductions in mean change in A1C level from baseline to week 26, compared with those on placebo. The findings were published in the Journal of the American Medical Association.
Study links better glycemic control with semaglutide use in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.